Pharmacotherapies for COPD

Stanley Ejiofor, Alice M Turner

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)
146 Downloads (Pure)


This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines.

Original languageEnglish
Pages (from-to)17-34
Number of pages18
JournalClinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
Publication statusPublished - 2013


Dive into the research topics of 'Pharmacotherapies for COPD'. Together they form a unique fingerprint.

Cite this